Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE

NCT01059526 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01059526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE
Lead sponsor
Shire
Phase
Observational
Overall status
Completed
Start date
February 1, 2010
Completion date
June 1, 2014
Enrollment
81 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)